About Bio-Thera Solutions
Bio-Thera Solutions is a commercial-stage biopharmaceutical company based in Guangzhou, Guangdong Province, founded in 2003 and listed on the Shanghai STAR Market (688177). Guided by the motto "Innovation for Life", it develops next-generation innovative medicines and biosimilars for cancer, autoimmune, cardiovascular, ophthalmic and other serious diseases.
Its products and candidates include biosimilars of adalimumab and other reference antibodies, an anticoagulant approved in China, antibody-drug conjugate (ADC) programmes targeting Trop2 and FRα, anti-PD-1 antibodies and autoimmune disease candidates. Several of its molecules have gained approvals in China, the United States, the European Union, the United Kingdom, Switzerland and Brazil, and the company maintains commercialization agreements with international partners such as STADA and Hikma.
Its Antibody Industrial Park in the Yonghe Development Zone of Guangzhou covers about 40,000 square metres with operational capacity of roughly 66,500 litres across stainless-steel and single-use bioreactors, with further expansion under construction. Bio-Thera runs six core technology platforms spanning antibody discovery, engineering, conjugates, process development and quality research aligned with NMPA, FDA and EMA standards.
Its products and candidates include biosimilars of adalimumab and other reference antibodies, an anticoagulant approved in China, antibody-drug conjugate (ADC) programmes targeting Trop2 and FRα, anti-PD-1 antibodies and autoimmune disease candidates. Several of its molecules have gained approvals in China, the United States, the European Union, the United Kingdom, Switzerland and Brazil, and the company maintains commercialization agreements with international partners such as STADA and Hikma.
Its Antibody Industrial Park in the Yonghe Development Zone of Guangzhou covers about 40,000 square metres with operational capacity of roughly 66,500 litres across stainless-steel and single-use bioreactors, with further expansion under construction. Bio-Thera runs six core technology platforms spanning antibody discovery, engineering, conjugates, process development and quality research aligned with NMPA, FDA and EMA standards.